Table 3.
Clinical and bacteriological response rates at days 14–21 in two studies comparing azithromycin 2.0 g microspheres with either extended release clarithromycin or levofloxacin in patients with community-acquired pneumonia (D’Ignazio et al 2005; Drehobl et al 2005)
|
Drehobl et al 2005 |
D’Ignazio et al 2005 |
|||
|---|---|---|---|---|
| Azithromycin microspheres | Clarithromycin XL 1.0 g | Azithromycin microspheres | Levofloxacin 500 mg | |
| Clinical response | 92.6% (n = 202) | 94.7% (n = 209) | 89.7% (n = 174) | 93.7% (n = 209) |
| Bacteriological response | 93.0% (n = 100) | 92.1 (n = 127) | 90.1% (n = 91) | 92.3% (n = 104) |
| Clinical response by pathogen | ||||
| Haemophilus influenzae | 14/15 (93%) | 23/26 (88%) | 14/15 (93%) | 8/8 (100%) |
| Moraxella catarrhalis | 8/8 (100%) | 3/5 (60%) | 7/7 (100%) | 2/2 (100%) |
| Streptoccoccus pneumoniae | 17/19 (89%) | 25/27 (93%) | 11/14 (79%) | 10/12 (83%) |
| Chlamydia pneumoniae | 19/21 (90%) | 29/31 (94%) | 18/19 (94%) | 21/22 (95%) |
| Mycoplasma pneumoniae | 25/26 (96%) | 20/21 (95%) | 5/7 (71%) | 18/18 (100%) |
Abbreviation: XL, extended release.